Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - Candlesense
ALT Regulatory

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Pemvidutide is the only drug currently granted Fast Track Designation in AUD

Related Questions

What is the expected timeline for clinical‑trial milestones and potential FDA approval for Pemvidetide in AUD? How does Pemvidetide's market potential compare to existing treatments and competitors in the alcohol use disorder space? How will the Fast Track designation for Pemvidetide affect Altimmune's valuation and near‑term stock performance?
Find similar articles on Candlesense globenewswire